Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Giuseppe Vanella

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7280-1761; OpenAlex author ID A5067951642. Sources: OpenAlex.

Their work

Papers
25 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
78
Papers, trials and grants by year

2020: 2 papers · 2021: 7 papers · 2022: 2 papers · 2023: 5 papers · 2024: 3 papers · 2025: 5 papers · 2026: 1 paper

Papers 25

  1. Pancreatic adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in advanced pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.02.015↗
  2. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  3. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Co-author DOI 10.1016/j.dld.2025.03.009↗
  4. Endoscopic ultrasound-guided portal vein sampling and circulating tumor cells: the next frontier in pancreatic cancer, or a step too far? Co-author DOI 10.1055/a-2563-0211↗
  5. Gastrointestinal symptoms in the journey of pancreatic cancer patients. Co-author DOI 10.1080/14737140.2025.2517888↗
  6. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  7. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  8. Management of malignant Gastric Outlet Obstruction (mGOO) due to pancreatic cancer in the era of EUS-Gastrojejunostomy: an international practice survey and ca… Last author DOI 10.1007/s00464-024-10803-0↗
  9. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  10. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  11. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  12. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  13. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  14. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  15. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  16. Feasibility of therapeutic endoscopic ultrasound in the bridge-to-surgery scenario: The example of pancreatic adenocarcinoma. Co-author DOI 10.3748/wjg.v28.i10.976↗
  17. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  18. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  19. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  20. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  21. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  22. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  23. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  24. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  25. Diagnostic delay does not influence survival of pancreatic cancer patients. Co-author DOI 10.1177/2050640619879004↗

Closest collaborators

The 25 strongest of 78 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gabriele Capurso · 10 shared papers, 2020–2026 · strength 1.60
  2. Massimo Falconi · 5 shared papers, 2022–2026 · strength 0.96
  3. Michele Reni · 5 shared papers, 2022–2026 · strength 0.96
  4. Paolo Giorgio Arcidiacono · 5 shared papers, 2021–2025 · strength 0.82
  5. Lívia Archibugi · 5 shared papers, 2020–2025 · strength 0.64
  6. Ruggero Ponz de Leon Pisani · 2 shared papers, 2025 · strength 0.44
  7. Marina Macchini · 2 shared papers, 2025–2026 · strength 0.41
  8. Giovanni Guarneri · 2 shared papers, 2025–2026 · strength 0.41
  9. Giulia Orsi · 2 shared papers, 2025–2026 · strength 0.41
  10. Diego Palumbo · 2 shared papers, 2023–2026 · strength 0.37
  11. Domenico Tamburrino · 2 shared papers, 2022–2025 · strength 0.33
  12. Maria Chiara Petrone · 2 shared papers, 2023–2025 · strength 0.32
  13. Matteo Tacelli · 2 shared papers, 2023–2025 · strength 0.32
  14. Gemma Rossi · 2 shared papers, 2023–2025 · strength 0.32
  15. Federico Canzian · 3 shared papers, 2021–2023 · strength 0.29
  16. Giulia Martina Cavestro · 3 shared papers, 2021–2023 · strength 0.29
  17. John P. Neoptolemos · 3 shared papers, 2021–2023 · strength 0.29
  18. Daniele Campa · 3 shared papers, 2021–2023 · strength 0.29
  19. Francesca Tavano · 3 shared papers, 2021–2023 · strength 0.29
  20. Manuel Gentiluomo · 3 shared papers, 2021–2023 · strength 0.29
  21. Casper H.J. van Eijck · 3 shared papers, 2021–2023 · strength 0.29
  22. Pavel Souček · 3 shared papers, 2021–2023 · strength 0.29
  23. Raffaele Pezzilli · 3 shared papers, 2021–2023 · strength 0.29
  24. Beatrice Mohelníková-Duchoňová · 3 shared papers, 2021–2023 · strength 0.29
  25. Stefano Crippa · 2 shared papers, 2022–2023 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.